<DOC>
	<DOCNO>NCT00947427</DOCNO>
	<brief_summary>Canakinumab fully human anti-interleukin-1β ( anti-IL-1β ) monoclonal antibody ( IgG-1 class ) . Canakinumab design bind human IL-1β functionally neutralize bioactivity pro-inflammatory cytokine . The study two-arm , multicenter , randomize , double-masked , placebo-controlled clinical trial . 66 subject randomly assign receive either monthly subcutaneous injection 2.0 mg/kg Canakinumab , placebo 12 month . All group receive standard intensive diabetes treatment insulin dietary management . Participants randomly assign Canakinumab treatment placebo receive total 12 injection one year . All subject follow 1 year treatment plus 1- 3 year additional follow-up study end . Enrollment expect occur two year .</brief_summary>
	<brief_title>Canakinumab Study Individuals With Newly Diagnosed Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Between age 645 year Be within 3months ( 100 day ) diagnosis type 1 diabetes Must least one diabetesrelated autoantibody present Must stimulate Cpeptide level &gt; 0.2 pmol/ml measure mixed meal tolerance test ( MMTT ) conduct least 21 day diagnosis within 37 day randomization If participant female reproductive potential , must willing avoid pregnancy negative pregnancy test 12 month treatment additional 3 month complete treatment Be least one month time last live immunization receive Willing forgo live vaccination 24 month Must willing comply intensive diabetes management Must weigh least 20 kg ( 44 lb ) study entry Are immunodeficient clinically significant chronic lymphopenia ( low white blood cell count ) Have active infection Have positive PPD test result Be currently pregnant lactating , anticipate get pregnant Ongoing use medication know influence glucose tolerance Require use immunosuppressive agent Have serologic evidence current past HIV , Hepatitis B , Hepatitis C infection Have complicate medical issue abnormal clinical laboratory blood count result interfere study conduct ; history malignancy Be currently participate another type 1 diabetes treatment study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>newly diagnose T1D</keyword>
	<keyword>T1D</keyword>
	<keyword>canakinumab</keyword>
	<keyword>anti IL-1</keyword>
</DOC>